Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

• Status: Terminated
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether standard medications approved for Alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or reduced decline.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: Ortho-McNeil Neurologics, Inc.
• Treatments: Donepezil; Galantamine

Criteria

Inclusion Criteria:

• Must meet diagnosis of mild Alzheimer's disease

• Must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study

• If female, must be post-menopausal

• Must be able to swallow tablets

Exclusion Criteria:

• Metal implants or medical devises unsafe for MRI use

• Pre-menopausal female

• HIstory of recent head injury

• Significant major, life-threatening illness or injury (e.g., stroke, AIDS, etc.)

• Vascular dementia or any dementia other than Alzheimer's Disease

• History of significant alcoholism or drug abuse

• History of seizure disorder, developmental delay or major psychiatric illness